- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Advances in Preventive Medicine
Volume 2013 (2013), Article ID 190190, 9 pages
North-South Corridor Demonstration Project: Ethical and Logistical Challenges in the Design of a Demonstration Study of Early Antiretroviral Treatment for Long Distance Truck Drivers along a Transport Corridor through South Africa, Zimbabwe, and Zambia
1Department of Global Health, Academic Medical Center, University of Amsterdam & Amsterdam Institute for Global Health and Development, Trinity Buildings, Building C, Pietersbergweg 17, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
2Wits Reproductive Health and HIV Institute, The University of the Witwatersrand, South Africa
Received 7 October 2012; Revised 6 February 2013; Accepted 1 March 2013
Academic Editor: Marie-Claude Boily
Copyright © 2013 G. B. Gomez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. J. Tatem, J. Hemelaar, R. R. Gray, and M. Salemi, “Spatial accessibility and the spread of HIV-1 subtypes and recombinants,” AIDS, vol. 26, no. 18, pp. 2351–2360, 2012.
- E. Lagarde, M. S. van der Loeff, C. Enel et al., “Mobility and the spread of human immunodeficiency virus into rural areas of West Africa,” International Journal of Epidemiology, vol. 32, no. 5, pp. 744–752, 2003.
- WHO/UNAIDS/UNICEF, “GLOBAL HIV/AIDS RESPONSE—epidemic update and health sector progress towards universal access,” Progress Report, 2011.
- G. O. Atilola, O. M. Akpa, and I. O. O. Komolafe, “HIV/AIDS and the long-distance truck drivers in South-West Nigeria: a cross-sectional survey on the knowledge, attitude, risk behaviour and beliefs of truckers,” Journal of Infection and Public Health, vol. 3, no. 4, pp. 166–178, 2010.
- K. D. Deane, J. O. Parkhurst, and D. Johnston, “Linking migration, mobility and HIV,” Tropical Medicine and International Health, vol. 15, no. 12, pp. 1458–1463, 2010.
- C. A. Varga, “Coping with HIV/AIDS in Durban's commercial sex industry,” AIDS Care—Psychological and Socio-Medical Aspects of AIDS/HIV, vol. 13, no. 3, pp. 351–365, 2001.
- S. Delany-Moretlwe, B. Bello, P. Kinross, et al., “HIV prevalence and risk in long distance truck drivers in South Africa: results from a national cross-sectional survey,” Submitted for publication.
- K. Molesworth, “Mobility and health: the impact of transport provision on direct and indirect determinants of access to health services,” 2011.
- “HIV and STD prevalence among bus and truck drivers in Cameroon,” AIDS Analysis Africa, vol. 4, no. 5, article 2, 1994.
- J. Bwayo, F. Plummer, M. Omari et al., “Human immunodeficiency virus infection in long-distance truck drivers in East Africa,” Archives of Internal Medicine, vol. 154, no. 12, pp. 1391–1396, 1994.
- G. G. Mbugua, L. N. Muthami, C. W. Mutura et al., “Epidemiology of HIV infection among long distance truck drivers in Kenya,” East African Medical Journal, vol. 72, no. 8, pp. 515–518, 1995.
- B. L. Diallo, M. Alary, S. Rashed, and A. Barry, “HIV prevalence, associated risk factors and evolution among truck drivers from 2001 to 2007 in Guinea,” Médecine Tropicale, vol. 71, no. 2, pp. 142–146, 2011.
- G. Ramjee and E. Gouws, “Prevalence of HIV among truck drivers visiting sex workers in Kwazulu-Natal, South Africa,” Sexually Transmitted Diseases, vol. 29, no. 1, pp. 44–49, 2002.
- O. Azuonwu, O. Erhabor, and N. Frank-Peterside, “HIV infection in long-distance truck drivers in a low income setting in the Niger Delta of Nigeria,” Journal of Community Health, vol. 36, no. 4, pp. 583–587, 2011.
- C. N. Morris and A. G. Ferguson, “Sexual and treatment-seeking behaviour for sexually transmitted infection in long-distance transport workers of East Africa,” Sexually Transmitted Infections, vol. 83, no. 3, pp. 242–245, 2007.
- C. N. Morris and A. G. Ferguson, “Estimation of the sexual transmission of HIV in Kenya and Uganda on the trans-Africa highway: the continuing role for prevention in high risk groups,” Sexually Transmitted Infections, vol. 82, no. 5, pp. 368–371, 2006.
- A. G. Ferguson and C. N. Morris, “Mapping transactional sex on the Northern Corridor highway in Kenya,” Health and Place, vol. 13, no. 2, pp. 504–519, 2007.
- IOM, Regional Assessment on HIV-Prevention Needs of Migrants and Mobile Populations in Southern Africa, IOM, Geneva, Switzerland, 2010.
- Walvis Bay Corridor Group, January 2013, http://www.wbcg.com.na/about-us/wbcg-hivaids-help-desk.html.
- FHI, “Program Helps Communities in Transport Corridor,” 2007, http://fhi.org/en/CountryProfiles/Zambia/res_COHII_project.htm.
- FHI360, “Round 3—behavioural surveillance survey Zambia, 2006,” Long distance truck drivers in transportation routes with trend analysis 2000–2006, http://pdf.usaid.gov/pdf_docs/PNADK673.pdf.
- FHI, “Corridors of Hope III,” 2009, http://www.fhi360.org/projects/corridors-hope-iii-coh-iii.
- E. J. Beck, C. Avila, S. Gerbase, G. Harling, and P. de Lay, “Counting the cost of not costing HIV health facilities accurately: pay now, or pay more later,” Pharmacoeconomics, vol. 30, no. 10, pp. 887–902, 2012.
- M. S. Cohen, Y. Q. Chen, M. McCauley et al., “Prevention of HIV-1 infection with early antiretroviral therapy,” The New England Journal of Medicine, vol. 365, no. 6, pp. 493–505, 2011.
- WHO, “Antiretroviral Treatment as Prevention (TasP) of HIV and TB: 2012 programmatic update,” 2012, http://whqlibdoc.who.int/hq/2012/WHO_HIV_2012.12_eng.pdf.
- WHO, “The strategic use of antiretrovirals to help end the HIV epidemic,” 2012, http://www.who.int/hiv/pub/arv/strategic_use/en/index.html.
- E. M. Gardner, M. P. McLees, J. F. Steiner, C. Del Rio, and W. J. Burman, “The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection,” Clinical Infectious Diseases, vol. 52, no. 6, pp. 793–800, 2011.
- S. Rosen and M. P. Fox, “Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review,” PLoS Medicine, vol. 8, no. 7, Article ID e1001056, 2011.
- J. P. Hughes, J. M. Baeten, J. R. Lingappa et al., “Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples,” The Journal of Infectious Diseases, vol. 205, no. 3, pp. 358–365, 2012.
- R. Granich, S. Gupta, A. B. Suthar et al., “Antiretroviral therapy in prevention of HIV and TB: update on current research efforts,” Current HIV Research, vol. 9, no. 6, pp. 446–469, 2011.
- C. W. Dieffenbach and A. S. Fauci, “Universal voluntary testing and treatment for prevention of HIV transmission,” The Journal of the American Medical Association, vol. 301, no. 22, pp. 2380–2382, 2009.
- R. M. Granich, C. F. Gilks, C. Dye, K. M. de Cock, and B. G. Williams, “Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model,” The Lancet, vol. 373, no. 9657, pp. 48–57, 2009.
- P. J. Dodd, G. P. Garnett, and T. B. Hallett, “Examining the promise of HIV elimination by “test and treat” in hyperendemic settings,” AIDS, vol. 24, no. 5, pp. 729–735, 2010.
- R. H. Gray, M. J. Wawer, R. Brookmeyer et al., “Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda,” The Lancet, vol. 357, no. 9263, pp. 1149–1153, 2001.
- S. M. Blower, H. B. Gershengorn, and R. M. Grant, “A tale of two futures: HIV and antiretroviral therapy in San Francisco,” Science, vol. 287, no. 5453, pp. 650–654, 2000.
- M. G. Law, G. Prestage, A. Grulich, P. van de Ven, and S. Kippax, “Modelling the effect of combination antiretroviral treatments on HIV incidence,” AIDS, vol. 15, no. 10, pp. 1287–1294, 2001.
- R. F. Baggaley, G. P. Garnett, and N. M. Ferguson, “Modelling the impact of antiretroviral use in resource-poor settings,” PLoS Medicine, vol. 3, no. 4, article e124, 2006.
- J. W. Eaton, L. F. Johnson, J. A. Salomon et al., “HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa,” PLOS Medicine, vol. 9, no. 7, Article ID e1001245, 2012.
- J. R. Andrews, R. Wood, L. G. Bekker, K. Middelkoop, and R. P. Walensky, “Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care,” The Journal of Infectious Diseases, vol. 206, no. 4, pp. 543–551, 2012.
- N. S. Padian, S. I. McCoy, S. Manian, D. Wilson, B. Schwartländer, and S. M. Bertozzi, “Evaluation of large-scale combination HIV prevention programs: essential issues,” Journal of Acquired Immune Deficiency Syndromes, vol. 58, no. 2, pp. e23–e28, 2011.
- G. P. Garnett, S. Becker, and S. Bertozzi, “Treatment as prevention: translating efficacy trial results to population effectiveness,” Current Opinion in HIV and AIDS, vol. 7, no. 2, pp. 157–163, 2012.
- Department of Health (Republic of South Africa), “The South African antiretroviral treatment guidelines,” 2010, http://apps.who.int/medicinedocs/documents/s19153en/s19153en.pdf.
- Ministry of Health (Government of the Republic of Zambia), “Adult and Adolescent antiretroviral therapy protocols,” 2010, http://www.tinytimandfriendszambia.org/index_htm_files/ARTguidelinesadults2010.pdf.
- National AIDS council notice (Zimbabwe), January 2013, http://www.nac.org.zw/sites/default/files/Zimbabwe-adopts-new-WHO-ART-guidelines.pdf.
- R. T. Lester, P. Ritvo, E. J. Mills et al., “Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial,” The Lancet, vol. 376, no. 9755, pp. 1838–1845, 2010.
- B. A. Larson, A. Brennan, L. McNamara et al., “Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa,” Bulletin of the World Health Organization, vol. 88, no. 9, pp. 675–680, 2010.
- Gilead, “Press release: U.S. FDA Approves Gilead's Stribild, a Complete Once-Daily Single Tablet Regimen for Treatment-Naïve Adults with HIV-1 Infection,” 2012, http://www.gilead.com/pr_1728981.
- UNAIDS, Costing Guidelines for HIV Prevention Strategies, 2000.
- DoH, South African Good Clinical Practice Guidelines, Department of Health, Pretoria, South Africa, 2006.
- ICH, Guideline for Good Clinical Practice, ICH Expert Working Group, 1996.
- UNAIDS, The Good Participatory Practice (GPP) Guidelines and Tools for Biomedical HIV Prevention Trials, UNAIDS, Geneva, Switzerland, 2011.
- P. E. Sax, E. DeJesus, A. Mills et al., “Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks,” The Lancet, vol. 379, no. 9835, pp. 2439–2448, 2012.
- E. DeJesus, J. K. Rockstroh, K. Henry et al., “Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial,” The Lancet, vol. 379, no. 9835, pp. 2429–2438, 2012.
- AIDSMeds, “Activists Protest Stribild’s $28, 500 Price Tag,” 2012, http://www.aidsmeds.com/articles/hiv_stribild_cost_1667_22878.shtml.
- DoH, “National Strategic Plan for HIV, TB ad STIs for 2012–2016,” 2012, http://www.doh.gov.za/docs/stratdocs/2012/NSPfull.pdf.